Delivery Order SPE2DB20D3103-SPE2DB24FM9M6
Award Date 3/7/24
Potential Completion Date 3/8/24
Potential Value $10K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of XIFAXAN 550 mg tablets. The order, valued at $5,473.81, has an ultimate completion date of April 8, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide XIFAXAN 550 mg tablets. The total ceiling value of this delivery order is $6,847.23, and the period of performance runs through March 12, 2024. This delivery order is issued under an indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp with a potential value of $999,999,999.00 and a...
- The U.S. Defense Logistics Agency (DLA) awarded a $4,818.35 firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of XIFAXAN 550 mg tablets. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for AmerisourceBergen to deliver...
- The U.S. government's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide XIFAXAN 550 mg tablets. The contract, valued at $26,667.99, has a period of performance through March 21, 2024. Amerisourcebergen Drug Corp is the prime contractor and this delivery order is issued under a larger indefinite delivery contract (IDC) with DLA Troop Support Medical,...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp's Corporate Office Division a $10,725.46 Firm Fixed Price Delivery Order contract for the supply of 4,558,997,746 units of the pharmaceutical product XIFAXAN 550 MG TABLET 60S. This delivery order was placed under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of...
- The Defense Logistics Agency (DLA) awarded a $39,961.11 firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of XIFAXAN 550 MG tablets. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00, to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to supply XIFAXAN 550 MG TABLET 60S to support military treatment programs and facilities. The contract, valued at $10,960.48, has an ultimate completion date of April 3, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA with a potential value of $999,999,999.00 and a performance period...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply the pharmaceutical product XIFAXAN 550 mg tablets. The contract has a ceiling value of $82,211.95 and an ultimate completion date of March 21, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31,...
- Amerisourcebergen Drug Corp, through its Corporate Office division, has been awarded a $13,055.53 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide XIFAXAN 550 MG TABLET 60S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
- The Defense Logistics Agency (DLA) awarded a $5,431.75 firm-fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of XIFAXAN 550 MG TABLET 60S. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB24FM9M6Delivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a wholly owned subsidiary of Cencora, Inc. doing business as Amerisourcebergen, to provide XIFAXAN 550 MG TABLET 60S. The award has a potential value of $10,402.04 and a performance period through March 8, 2024. This delivery order is issued under an indefinite delivery contract (IDC) with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025, which serves as the primary contract vehicle for Amerisourcebergen to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. The contract does not have a set-aside designation.
Generated 6/6/24, 10:11 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 3/7/24 |